NO20055655L - Anvendelse av azetidinkarboksamidderivater i terapi - Google Patents

Anvendelse av azetidinkarboksamidderivater i terapi

Info

Publication number
NO20055655L
NO20055655L NO20055655A NO20055655A NO20055655L NO 20055655 L NO20055655 L NO 20055655L NO 20055655 A NO20055655 A NO 20055655A NO 20055655 A NO20055655 A NO 20055655A NO 20055655 L NO20055655 L NO 20055655L
Authority
NO
Norway
Prior art keywords
sup
therapy
azetidinecarboxamide
derivatives
aryl
Prior art date
Application number
NO20055655A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055655D0 (no
Inventor
David Reginald Adams
James Edward Paul Davidson
Michael John Bickerdike
Allan Fletcher
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Publication of NO20055655D0 publication Critical patent/NO20055655D0/no
Publication of NO20055655L publication Critical patent/NO20055655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055655A 2003-05-01 2005-11-30 Anvendelse av azetidinkarboksamidderivater i terapi NO20055655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0310057 2003-05-01
PCT/GB2004/001812 WO2004096209A1 (en) 2003-05-01 2004-04-29 The use of azetidinecarboxamide derivatives in therapy

Publications (2)

Publication Number Publication Date
NO20055655D0 NO20055655D0 (no) 2005-11-30
NO20055655L true NO20055655L (no) 2006-01-31

Family

ID=33397042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055655A NO20055655L (no) 2003-05-01 2005-11-30 Anvendelse av azetidinkarboksamidderivater i terapi

Country Status (16)

Country Link
US (1) US20060276452A1 (https=)
EP (1) EP1617839B1 (https=)
JP (1) JP2006525297A (https=)
KR (1) KR20060017763A (https=)
CN (1) CN1780615A (https=)
AT (1) ATE398449T1 (https=)
AU (1) AU2004233644A1 (https=)
BR (1) BRPI0409959A (https=)
CA (1) CA2524245A1 (https=)
DE (1) DE602004014484D1 (https=)
EA (1) EA200501703A1 (https=)
MX (1) MXPA05011472A (https=)
NO (1) NO20055655L (https=)
NZ (1) NZ543322A (https=)
WO (1) WO2004096209A1 (https=)
ZA (1) ZA200508835B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) * 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
US20090221644A1 (en) * 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
US20090264470A1 (en) * 2006-02-21 2009-10-22 Bennett Teresa A CB1 Antagonists and Inverse Agonists
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US11141404B1 (en) 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
AU2022362107A1 (en) * 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPH03264562A (ja) * 1989-05-22 1991-11-25 Hokuriku Seiyaku Co Ltd ピペリジン誘導体
JP3194355B2 (ja) * 1996-10-24 2001-07-30 宇部興産株式会社 ピペリジン化合物及びその製法
WO1999037612A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders
GB9917386D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-II
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
AU2004234125A1 (en) * 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders

Also Published As

Publication number Publication date
ATE398449T1 (de) 2008-07-15
CA2524245A1 (en) 2004-11-11
EP1617839A1 (en) 2006-01-25
NO20055655D0 (no) 2005-11-30
JP2006525297A (ja) 2006-11-09
US20060276452A1 (en) 2006-12-07
NZ543322A (en) 2009-03-31
AU2004233644A1 (en) 2004-11-11
ZA200508835B (en) 2006-12-27
BRPI0409959A (pt) 2006-04-25
CN1780615A (zh) 2006-05-31
EA200501703A1 (ru) 2006-06-30
DE602004014484D1 (de) 2008-07-31
EP1617839B1 (en) 2008-06-18
KR20060017763A (ko) 2006-02-27
MXPA05011472A (es) 2005-12-12
WO2004096209A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
NO20055655L (no) Anvendelse av azetidinkarboksamidderivater i terapi
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
ATE440603T1 (de) 8-hydroxychinolinderivate
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
CA2478374A1 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
CY1107974T1 (el) Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
ATE341550T1 (de) Quinolinyl-pyrrolopyrazole
ATE384058T1 (de) Thiazolderivate
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
GEP20063751B (en) 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
MY139676A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application